Gefitinib-associated vitiligo: Report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation

Dermatology Online Journal

Volumn 19, Issue 10, 2013, Pages

  Jalalat, Sheila Z ^a   Cohen, Philip R ^b,c,d,e  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d University of Texas Health Science Center at Houston   (United States)

^e UNIVERSITY OF SAN DIEGO   (United States)

Author keywords

Cancer; Drug; EGFR inhibitors; Gefitinib; Hypopigmentation; Vitiligo

Indexed keywords

GEFITINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; DISEASE COURSE; DRUG RESPONSE; HUMAN; HUMAN TISSUE; HYPOPIGMENTATION; MALE; NECK DISSECTION; PAROTID GLAND CARCINOMA; PAROTIDECTOMY; RECURRENT CANCER; SKIN COLOR; SKIN EXAMINATION; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; VITILIGO; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; MIDDLE AGED; PAROTID GLAND TUMOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HUMANS; MALE; MIDDLE AGED; PAROTID NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VITILIGO;

EID: 84886899540     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. ME Lacouture, BL Melosky: Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett. 2007;12(6)1-5.
2. Tan EH, Chan A: Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother. 2009;43:1658-1666.
3. Pasual JC, Belinchon I, Sivera F, Yuste A: Severe cutaneous toxicity following treatment with gefitinib (ZD1839). Br J Dermatol. 2005;153:1222-1223.
4. Lagran de Martinez Z, Raton JA, Lasa O, Acebo E, Diaz-Perez JL: Acneiform eruption from epidermal growth factor inhibitors. Actas Dermosifiliogr. 2005;96:450-454.
5. Wyatt AJ, Leonard GD, Sachs DL: Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol. 2006;7(1):45-63.
6. Segart S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425-1433.
7. Cohen PR, Escudier SM, Kurzrock R: Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. Am J Clin Dermatol. 2011;12(1):63-67.
8. Brazzelli V, Grasso V, Barbaccia V, Manna G, Rivetti N, Zecca M, Giovanna G, Vassallo C, Borroni G. Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib. Acta Derm Venereol. 2012;92: 193-220.
9. Wehrle-Haller B. The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res. 2003; 16: 287-296.
10. Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF-KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol. 1998; 111:233-238.
11. Yoshida H, Kunisada T, Grimm T, Nishimura EK, Nishioka E, Nishikawa SI. Review: melanocyte migration and survival controlled by SCF/c-kit expression. J Investig Dermatol Symp Proc. 2001; 6: 1-5.
12. Rao MV, Shayne M: Vitiligo in the affected breast during neo-adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2009;117:197-198.
13. Gokhale BB: Cyclophosphamide and vitiligo. Int J Dermatol. 1979;18(1):92.
14. Gokhale BB, Parakh AP: Cyclophosphamide in vitiligo. Indian J Dermatol. 1983;28(1):7-10.
15. Arya V, Bansal M, Girard L, Arya S, Valluri A: Vitiligo at injection site of PEG-IFN-a 2a in two patients with chronic hepatitis c: case report and literature review. Case Rep Dermatol. 2010;2:156-164.
16. Sriprakash K, Godbolt A: Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma. Australas J Dermatol. 2009;50:211-213.
17. Fujita M, High WA, Asgari S, Lewis KD, Gonzalez R: Development of vitiligo during melanoma treatment with a novel surviving inhibitor: a case report and review of the literature. Int J Dermatol. 2009;48:426-430.
18. Sanli H, Akay BN, Arat M, Kocyigit P, Akan H, Beksac M, Iihan O: Vitiligo after hematopoietic cell transplantation: six cases and review of the literature. Dermatology. 2008;216:349-354.
19. Legros L, Cassuto JP, Ortonne JP: Imatinib mesilate (Glivac): a systemic depigmentation agent for extensive vitiligo? Br J Dermatol. 2005;153:691-692.
20. Curzytek K, Pietowska J, Spiewak R: Vitiligo induced by drugs: a meta-analysis of reported cases. (Abstract). Allergy. 2007;62:447.
21. Schmid-Wendtner MH, Wendtner CM, Volkenandt M, Heinemann V: Clinical picture: leopard-like vitiligo with capecitabine. Lancet. 2001;358:1575.
22. Martín-García RF, del R, Camacho N, Sánchez JL: Chloroquine-induced, vitiligo-like depigmentation. J Am Acad Dermatol. 2008;48:981-983.
23. Selvaag E. Chloroquine-induced vitiligo: a case report and review of the literature. Acta Derm Venereol. 1996;76:166-167.
24. Sabaté M, Bosch A, Pedrós C, Figueras A: Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease. Ann Pharmacother. 1999;33:1228-1229.
25. Nilforoushzadeh MA, Keshtmand G, Jaffary F, Kheirkhah A: Diphencyprone induced vitiligo: a case report. Case Report Med. 2012;2012:
26. Rampertaap MP: Vitiligo-like syndrome following the use of fluphenazine enanthate. Mo Med. 1985;82(1):24-26.
27. Chu CY, Liu YL, Chiu HC, Jee SH: Dopamine-induced apoptosis in human melanocytes involves generation of reactive oxygen species. Br J Dermatol. 2006;154:1071-1079.
28. Schallreuter KU: Beta-adrenergic blocking drugs may exacerbate vitiligo. Br J Dermatol. 1995;132(1):168-169.
29. Aubin F, Cahn JY, Ferrand C, Angonin R, Humbert P, Tiberghien P: Extensive vitiligo after ganciclovir treatment of GvHD in a patient who had received donor T cells expressing herpes simplex virus thymidine kinase. Lancet. 2000;55:626-627.
30. Burge MR, Carey JD: Vitiligo associated with subcutaneous insulin lispro infusion in type 1 diabetes. Diabetes Care. 2004;27(1):275-276
31. Toosi S, Orlow SJ, Manga P: Vitiligo-Inducing Phenols Activate the Unfolded Protein Response in Melanocytes Resulting in Upregulation of IL6 and IL8. J Invest Dermatol. 2012; doi: 10.1038/jid.2012.181
32. Nasca MR, Micali G, Pulvirenti N, Licastro Cicero R: Transient leucoderma appearing in an untreated area following contact immunotherapy for alopecia areata. Eur J Deramtol. 1998;8:125-126.
33. Brown-Harrell V, Nitta AT, Goble M: Apparent exacerbation of vitiligo syndrome in a patient with pulmonary Mycobacterium avium complex disease who received clofazimine therapy. Clin Infect Dis. 1996;22:581-582.
34. Ramírez-Hernández M, Marras C, Martínez-Escribano JA: Infliximab-induced vitiligo. Dermatology. 2005;210:79-80.
35. Seçkin D, Durusoy C, Sahin S: Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol. 2004;21:577-579.
36. Bernstein D, Reddy KR, Jeffers L, Schiff E: Canities and vitiligo complicating interferon therapy for hepatitis C. Am J Gastroenterol. 1995;90:1176-1177.
37. Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT: Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin Immunol. 2008;127:123-9.
38. Weiss GR, Fehrenkamp SH, Tokaz LK, Sunderland MC: Vitiligo and Graves' disease following treatment of malignant melanoma with recombinant human interleukin 4. 1996;192:283-285.
39. Raanani P, Goldman JM, Ben-Bassat I: Challenges in oncology. case 3. depigmentation in a chronic myeloid leukemia patient treated with STI-571. J Clin Oncol. 2002;20:869-870.
40. Heidary N, Naik H, Burgin S: Chemitherapeutic agents and the skin: an update. J Am Acad Dermatol. 2008;54:545-570.
41. Mendonca CO, Yates VM: Permanent facial hypopigmentation following treatment with imiquimod cream. Clin Exp Dermatol. 2006;31:721-722.
42. Jacob SE, Blyumin M: Vitiligo-like hypopigmentation with poliosis following treatment of superficial basal cell carcinoma with imiquimod. Dermatol Surg. 2008;34:844-845.
43. Senel E, Seckin D: Imiquimod-induced vitiligo-like depigmentation. Indian J Dermatol Venereol Leprol. 2007;73:423.
44. Brown T, Zirvi M, Cotsarelis G, Gelfand JM: Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol. 2005;52:715-716.
45. Al-Dujaili Z, Hsu S: Imiquimod-induced vitiligo. Dermatol Online J. 2007;13:10.
46. Alonso-Castro L, Rios-Buceta Luis, Vano-Galvan S, Moreno C, Soria-Rivas A, Jaen Pedro. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma. J Am Acad D ermatol. 2013;69:28-29.